Literature DB >> 12482570

Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders.

Jaap M Middeldorp1, Antoinette A T P Brink, Adriaan J C van den Brule, Chris J L M Meijer.   

Abstract

Epstein-Barr virus (EBV) is associated with a still growing spectrum of clinical disorders, ranging from acute and chronic inflammatory diseases to lymphoid and epithelial malignancies. Based on a combination of in vitro and in vivo findings, EBV is thought to contribute in the pathogenesis of these diseases. The different EBV gene expression patterns in the various disorders, suggest different EBV-mediated pathogenic mechanisms. In the following pages, an overview of the biology of EBV-infection is given and functional aspects of EBV-proteins are discussed and their putative role in the various EBV-associated disorders is described. EBV gene expression patterns and possible pathogenic mechanisms are discussed. In addition, expression of the cellular genes upregulated by EBV in vitro is discussed, and a comparison with the in vivo situation is made.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12482570     DOI: 10.1016/s1040-8428(02)00078-1

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  66 in total

1.  Evidence of an oncogenic gammaherpesvirus in domestic dogs.

Authors:  Shih-Hung Huang; Philip J Kozak; Jessica Kim; Georges Habineza-Ndikuyeze; Charles Meade; Anita Gaurnier-Hausser; Reema Patel; Erle Robertson; Nicola J Mason
Journal:  Virology       Date:  2012-03-08       Impact factor: 3.616

2.  Viral response to chemotherapy in endemic burkitt lymphoma.

Authors:  Weihua Tang; Paula Harmon; Margaret L Gulley; Charles Mwansambo; Peter N Kazembe; Francis Martinson; Clifford Wokocha; Shannon C Kenney; Irving Hoffman; Carlie Sigel; Susan Maygarden; Mariah Hoffman; Carol Shores
Journal:  Clin Cancer Res       Date:  2010-03-16       Impact factor: 12.531

Review 3.  Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation.

Authors:  Francesco Pegoraro; Claudio Favre
Journal:  Ann Hematol       Date:  2021-02-06       Impact factor: 3.673

4.  Aggressive natural killer cell leukemia: report of a Chinese series and review of the literature.

Authors:  John Ryder; Xiaoqin Wang; Liming Bao; Sherilyn A Gross; Fu Hua; Richard D Irons
Journal:  Int J Hematol       Date:  2007-01       Impact factor: 2.490

Review 5.  Structure, function and physiological consequences of virally encoded chemokine seven transmembrane receptors.

Authors:  M M Rosenkilde; M J Smit; M Waldhoer
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

6.  Epstein-Barr virus transcription activator R upregulates BARF1 expression by direct binding to its promoter, independent of methylation.

Authors:  E K Hoebe; C Wille; E S Hopmans; A R Robinson; J M Middeldorp; S C Kenney; A E Greijer
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

7.  Incidence of Epstein-Barr virus in Syrian women with breast cancer: A tissue microarray study.

Authors:  Tahar Aboulkassim; Amber Yasmeen; Nizar Akil; Gerald Batist; Ala-Eddin Al Moustafa
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  The role of promoter methylation in Epstein-Barr virus (EBV) microRNA expression in EBV-infected B cell lines.

Authors:  Do Nyun Kim; Yoon Jae Song; Suk Kyeong Lee
Journal:  Exp Mol Med       Date:  2011-07-30       Impact factor: 8.718

Review 9.  Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes.

Authors:  Abhik Saha; Erle S Robertson
Journal:  Clin Cancer Res       Date:  2011-03-03       Impact factor: 12.531

10.  Characteristics of Epstein-Barr virus-associated gastric cancer: a study of 235 cases at a comprehensive cancer center in U.S.A.

Authors:  Camtu D Truong; Wei Feng; Wei Li; T Khoury; Q Li; S Alrawi; Yingyan Yu; Keping Xie; James Yao; Dongfeng Tan
Journal:  J Exp Clin Cancer Res       Date:  2009-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.